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Result: The human pancreas cDNA library was constructed
successfully. The reconstructed bait plasmid (pGBKT7-HCV
NS4B) was transformed into yeast cells AHl09 successfully.
Eight proteins interacting with HCV NS4B were found.
Conclusion: Some of the eight pancreatic proteins may be
related with metabolisms of glucose and lipid.
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Background: Immortalized human hepatocytes HuS-E/2
cells cultured in Hollow ﬁber (HF) support the blood-borne
hepatitis C virus (HCVbb) infection in vitro. But several
limits of the HF system stand in the way of its usage
for HCV research. This study is to evaluate the efﬁciency of
different three dimensional (3-D) culture systems for HCVbb
ampliﬁcation in vitro.
Methods: HuS-E/2 cells were cultured in different 3-D cell
culture systems, HF, hydrocell plate (HP) and mebiol gel
(MG). Serum and plasma from hepatitis C patients were used
for infection of the cells. Plasma was pre-treated with Ca2+
containing solution for the infection. Cell proliferation was
monitored with XTT assay. HCV ampliﬁcation in 3-D cultured
cells was measured with real time PCR.
Results: Stable cell proliferation was observed in both
HF and MG system. HCVbb ampliﬁcation in HuS-E/2 cells
which were cultured in HF, HP and MG exhibited the similar
patterns although the titer in cells of different systems is
variational.
Conclusion: All three 3-D systems can support the
proliferation of HCVbb. The selection of the system for
research depends on other factors such as the objective of
the research, culture condition and so on.
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Patients with hepatitis C virus (HCV)-related decompensated
cirrhosis are associated with a poor prognosis. Although
liver transplantation (LT) offers an effective treatment,
HCV reinfection of the transplanted graft is a critical
and almost inevitable complication with major inﬂuence
on graft- and patient survival. Antiviral therapy of this
patient population is difﬁcult, the use of interferon and
ribavirin might expose these patients to severe treated-
related side effects as a large proportion of them have
pre-existing hematological cytopenias. However, antiviral
treatment in patients with advanced liver cirrhosis is
a potential option for two reasons: ﬁrst, clearing or
suppressing HCV before LT may reduce or eliminate the
risk of recurrent hepatitis C in the transplanted liver and
thereby improve survival; second, clearing HCV in cirrhotic
patient may halt disease progression and avoid the need
for transplantation. Basd on AASLD and ESAL guidelines,
antiviral therapy in this patient population is generally
recommended, but indication, optimal timing, dose and
duration of therapy are not clearly deﬁned. In this article,
the results obtained by antiviral regimens administered to
HCV-related decompensated cirrhosis are discussed.
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Background: A high risk of chronicity is the major concern
of HCV infection and chronic infection often leads to liver
cirrhosis and hepatocellular carcinoma. Although proportion
of patients achieving a sustained virological response has
been increased by the introduction of combination therapy
of pegylated-IFN-alpha and ribavirin, still half of the
patients exhibits no response to the therapy. One of the
mechanisms for the establishment of persistent infection
of HCV is the escape from the host immune system.
To eliminate HCV from the hepatocytes of the patients
without possible cytotoxity due to anover induction of host
immunity, we generated a therapeutic construct, cMR3, by
which type I IFN is selectively induced in HCV infected
cells.
Methods: The cMR3 is composed of the N-terminal part
of the interferon regulatoryfactor 7 (IRF7) possessing a
dominant active function, the sequences speciﬁcally cleaved
by HCV NS3/4A protease and an ER anchor, and exhibits
apotent IFN inducing activity in HCV infected cells. After
cleavage by the HCV protease, the processed cMR3 migrates
into the nucleus and activates various IFN promoters
including IFN-alpha6, IFNbeta, and IFN stimulated response
element.
Results: The speciﬁc activation ofthe IFN promoters was
observed in both HCV replicon cells and JFH1 virus infected
cells upon introduction of the cMR3 but not in cells infected
with JEVor DENV. Expression of viral protein and viral RNA
replication were also impaired by the introduction of cMR3
into the HCV replicon cells.
Conclusion: These results suggest that the selective
expression of type I IFN in the hepatocytes infected with
HCV by the introduction of the cMR3 might be feasibleto
eliminate HCV from the chronic hepatitis C patients without
liver damage.
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Background: Hepatitis C virus (HCV) infects about 170
million people worldwide and is a major cause of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
Several mechanisms have been proposed for the incidence
of HCC, including apoptosis resistance. CD44, an integral
cell membrane glycoprotein and adhesion molecule, plays
a critical role in a number of important cellular function
including activating anti-apoptosis signal pathway. The aim
of this study were to investigate the expression of CD44v6
in liver cancer tissues and to determine its correlation
with apoptosis resistance via upregulated activity of the
PI3K/AKT pathway.
Methods: We examined the expression of CD44 in liver
cancer tissues in patients with HCV-related HCC compared
with in liver tissues in health controls by Western blot and
the expression of CD44v6 in HCV replicon and JFH1-infected
cells compared with in Huh7 by FACS. Furthermore, we
investigated the apoptosis of CD44 knockdown HCV replicon
and HCV-infected cells treated by ActD compared with that
in negative control cells.
Results: HCV-related HCC liver cancer tissues expressed
signiﬁcantly higher CD44 protein levels than tissues in health
controls. Signiﬁcantly higher CD44v6 were observed in HCV
